ImmunoPrecise Antibodies Ltd.

Latest

Jul 31, 2020, 08:13 ET IPA's Human Anti-SARS-CoV-2 Therapeutic Antibodies Demonstrate Synergistic Neutralization

VICTORIA, BC, July 31, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a provider of best-in-class therapeutic antibody capabilities, is...


Jul 28, 2020, 08:23 ET IPA Awarded US$1.5M Bioscience Innovation Grant for Coronavirus Research from the North Dakota Department of Agriculture

VICTORIA, BC, July 28, 2020 /CNW/ -IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF) (FSE:TQB2), a best-in-class therapeutic antibody discovery company for the global...


Jul 20, 2020, 08:00 ET IPA Announces Repayment of Remaining 2018 Debentures and $3,811,205 in Warrant Exercises

VICTORIA, BC, July 20, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and...


Jul 13, 2020, 07:51 ET Functional, Human Antibodies Targeting SARS-CoV-2 Discovered Using IPA's Proprietary B cell Select™ and Single Step Cloning Hybridoma Technologies

IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals' genetically engineered OmniRat® strains producing human...


Jun 29, 2020, 12:48 ET IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2

IPA Announces Discovery of Functional Antibodies from Humans and Llama (VHH), Identified Using IPA Phage Display Technology VICTORIA, BC, June 29, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the...


Jun 22, 2020, 07:30 ET Collaborative COVID-19 Vaccine Project Between ImmunoPrecise Antibodies Europe and LiteVax BV, Funded Through TRANSVAC2

OSS, Netherlands, June 22, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), and LiteVax BV ("LiteVax") (the Netherlands), today...


Jun 11, 2020, 08:12 ET Recombinant SARS-CoV-2 Proteins Now Available For Research From ImmunoPrecise's European Subsidiary, UPE

UTRECHT, Netherlands, June 11, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) (Germany: TQB2) subsidiary U-Protein Express BV ("UPE") today...


Jun 04, 2020, 07:30 ET ImmunoPrecise Collaborates with the NIH and Integrated Biotherapeutics to Study the Structural Details of Antibodies with Therapeutic Potential to Treat or Prevent Coronavirus Disease 2019 (COVID-19)

VICTORIA, BC, June 4, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSXV: IPA) (OTCQB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for the...


May 27, 2020, 07:30 ET NSERC Awards Grant to Fund Collaboration Between ImmunoPrecise and the University of Victoria for the Generation of a Potential COVID-19 Antibody-Based Test in Canada that can Provide Real-Time

VICTORIA, May 27, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF), specialists in custom antibody discovery and development, today announced a...


May 15, 2020, 18:06 ET ImmunoPrecise Closes Oversubscribed Debenture Financing

VICTORIA, May 15, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has closed its previously announced...


May 15, 2020, 12:00 ET ImmunoPrecise Increases Financing to $2.592 Million

VICTORIA, May 15, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has increased its previously announced (see...


May 08, 2020, 07:51 ET ImmunoPrecise Increases Financing to $2.3 Million and Makes Payment in Respect of Deferred Purchase Price for IPA Europe and Immulease

VICTORIA, May 8, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) is pleased to announce that it has increased its previously announced (see news ...


May 06, 2020, 07:24 ET ImmunoPrecise Antibodies Increases Discovery Capabilities to Help Pinpoint Lead Drug Candidates with Addition of Octet HTX

VICTORIA, May 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for...


Apr 24, 2020, 13:26 ET ImmunoPrecise Updates on State and Federal Funding

IPA Awarded Grant Focused on Coronavirus and Other Emerging Pathogens FARGO, ND, April 24, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), is...


Apr 17, 2020, 08:00 ET ImmunoPrecise Provides Updates on B Cell Select™ and Deep Display™ Programs for SARS-CoV-2 Antibody Discovery

We caution that this news release is not making any express or implied claims that we have the ability to eliminate the SARS-CoV-2 virus at this time. We further caution that we have not undertaken...


Apr 15, 2020, 09:07 ET ImmunoPrecise Participates in Public Consensus Statement, from the WHO, on Collaboration for Developing a COVID-19 Vaccine

VICTORIA, April 15, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) provides an update on its participation and support of global solidarity in...


Apr 14, 2020, 07:00 ET ImmunoPrecise Announces Agreement with Janssen

VICTORIA and CAMBRIDGE, MA, April 14, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a global leader in therapeutic antibody discovery and...


Apr 02, 2020, 08:35 ET ImmunoPrecise Announces Appointment of Yasmina Noubia Abdiche, Ph.D., as Chief Scientific Officer

VICTORIA, April 2, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF), a provider of best-in-class therapeutic antibody discovery capabilities for...


Mar 31, 2020, 09:40 ET ImmunoPrecise Announces Extension of Debentures and Completion of Debt Settlement of Previously Issued Debentures

VICTORIA, March 31, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) announces that it has extended maturity date for $2,000,000 of previously...


Mar 30, 2020, 16:12 ET ImmunoPrecise's Artificial Intelligence Partner, EVQLV, Submits First Panel of Optimized Antibody Sequences to Coronavirus for PolyTope(TM) mAb Therapy Program

We caution that this is still early stage research and development and is not making any express or implied claims that it has the ability to eliminate the SARS-CoV-2 virus at this time. We further...


Mar 12, 2020, 07:00 ET ImmunoPrecise Announces the Launch of PolyTope mAb Therapy™ to Tackle Coronavirus Pandemic

New Approach Entails a Defined Antibody Combination Targeting Multiple Epitopes and Mechanisms of Viral Evasion VICTORIA, March 12, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") ...


Mar 10, 2020, 09:22 ET ImmunoPrecise Reports Record Quarterly and Nine Month Revenue and Positive Adjusted EBITDA

VICTORIA, March 10, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) today announced financial results for its fiscal year 2020 third quarter...


Mar 06, 2020, 17:44 ET ImmunoPrecise Announces Debt Settlement of Previously Issued Debentures

VICTORIA, March 6, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) announces that it wishes to settle up to $796,875 of previously issued...


Mar 02, 2020, 07:00 ET ImmunoPrecise Announces Artificial Intelligence Collaboration with EVQLV to Accelerate Vaccine and Antibody Discovery for SARS-CoV-2 Coronavirus

The partnership with the New York-based artificial intelligence company will focus on high-throughput computational antibody design to derive novel leads from ImmunoPrecise's platforms and accelerate ...


Feb 20, 2020, 14:39 ET ImmunoPrecise Launches Coronavirus Vaccine and Therapeutic Antibody Program

VICTORIA, Feb. 20, 2020 /CNW/ - ImmunoPrecise Antibodies Ltd (the "Company"), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, announces its commitment ...